Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive
NCT02279862
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
82
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
Ipilimumab
Sponsor
Bristol-Myers Squibb